New combo attack on early lung cancer
NCT ID NCT07379398
Summary
This study is testing whether a new two-in-one immunotherapy drug (QL1706) works better when given alongside a precise, high-dose form of radiation (SBRT) for people with early-stage non-small cell lung cancer. The main goal is to see if this combination can help control the cancer and prevent it from coming back for at least one year. Researchers will also closely monitor for any side effects in the 28 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.